Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Nov 18, 2014; 5(5): 653-659
Published online Nov 18, 2014. doi: 10.5312/wjo.v5.i5.653
Published online Nov 18, 2014. doi: 10.5312/wjo.v5.i5.653
Inhibition of rheumatoid arthritis by blocking connective tissue growth factor
Kazuhisa Nozawa, Yoshinari Takasaki, Department of Rheumatology, School of Medicine, Juntendo University, Tokyo 113-8421, Japan
Maki Fujishiro, Iwao Sekigawa, Institute for Environment and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba 261-7114, Japan
Iwao Sekigawa, Department of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Chiba 261-7114, Japan
Author contributions: All authors contributed to this paper.
Supported by Grant-in-Aid for Scientific Research (C), The Ministry of Education, Culuture, Sports, Science and Technology and The Institute for Environment and Gender-specific Medicine, Juntendo University Graduate School of Medicine
Correspondence to: Kazuhisa Nozawa, MD, PhD, Department of Rheumatology, School of Medicine, Juntendo University 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan. k-nozawa@juntendo.ac.jp
Telephone: +81-3-58021067 Fax: +81-3-58004893
Received: December 26, 2013
Revised: April 14, 2014
Accepted: July 17, 2014
Published online: November 18, 2014
Revised: April 14, 2014
Accepted: July 17, 2014
Published online: November 18, 2014
Core Tip
Core tip: Connective tissue growth factor (CTGF) plays an important role in the pathogenesis of rheumatoid arthritis (RA). We propose that CTGF is a potentially novel effector molecule in the pathogenesis of RA. Blocking the CTGF pathways by biological agents may have great beneficial effect in patients with RA.